Cargando…

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer

Radioimmunotherapy (RIT) has demonstrated efficacy with acceptable toxicity leading to approval in non-Hodgkin’s lymphoma, but has been slower to develop for the treatment of advanced solid tumors. Prostate cancer (PC) represents a good candidate for RIT based upon high exposure to circulating antib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tagawa, Scott T., Akhtar, Naveed H., Nikolopoulou, Anastasia, Kaur, Gurveen, Robinson, Brian, Kahn, Renee, Vallabhajosula, Shankar, Goldsmith, Stanley J., Nanus, David M., Bander, Neil H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3752585/ https://www.ncbi.nlm.nih.gov/pubmed/23986881 http://dx.doi.org/10.3389/fonc.2013.00214

Ejemplares similares

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Isolation and characterization of circulating tumor cells in prostate cancer
por: Diamond, Elan, et al.
Publicado: (2012)

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling
por: Fung, Edward K., et al.
Publicado: (2016)

Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow
por: Gakhar, Gunjan, et al.
Publicado: (2013)

ERG induces taxane resistance in castration-resistant prostate cancer
por: Galletti, Giuseppe, et al.
Publicado: (2014)

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016)

Targeting prostate cancer with radiolabelled bombesins
por: Maina, Theodosia, et al.
Publicado: (2006)

Prostate-Specific Membrane Antigen-Based Therapeutics
por: Akhtar, Naveed H., et al.
Publicado: (2012)

Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib
por: Beltran, Himisha, et al.
Publicado: (2014)

Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy
por: Kosuri, Satyajit, et al.
Publicado: (2012)

The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer
por: Smith, Michael J., et al.
Publicado: (2012)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody.
por: Smedley, H. M., et al.
Publicado: (1983)

MK591, a Second Generation Leukotriene Biosynthesis Inhibitor, Prevents Invasion and Induces Apoptosis in the Bone-Invading C4-2B Human Prostate Cancer Cells: Implications for the Treatment of Castration-Resistant, Bone-Metastatic Prostate Cancer
por: Sarveswaran, Sivalokanathan, et al.
Publicado: (2015)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Radiolabelled monoclonal antibodies in the treatment of metastatic cancer
por: Goldenberg, D.M.
Publicado: (2007)

Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
por: Uccelli, Licia, et al.
Publicado: (2017)

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees
por: Cortesi, Laura, et al.
Publicado: (2021)

Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer
por: Irelli, A., et al.
Publicado: (2014)

Impact of Progressive Site-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer on Subsequent Treatment Response
por: Yoshida, Soichiro, et al.
Publicado: (2022)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

The Application of Radiolabeled Targeted Molecular Probes for the Diagnosis and Treatment of Prostate Cancer
por: Cheng, Luyi, et al.
Publicado: (2023)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

A Case of Castration for Hypertrophied Prostate
Publicado: (1897)

Noninvasive Imaging of PSMA in Prostate Tumors with (89)Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives
por: Viola-Villegas, Nerissa Therese, et al.
Publicado: (2014)

Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device
por: Kirby, Brian J., et al.
Publicado: (2012)

The resurgence of estrogens in the treatment of castration-resistant prostate cancer
por: Moorthy, H. Krishna, et al.
Publicado: (2019)

Correction: Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device
por: Kirby, Brian J., et al.
Publicado: (2012)

Low Tumorigenic Response to 3,2′‐Dimethyl‐4‐aminobiphenyl Administration in the Prostate of Rats Castrated at Birth
por: Shirai, Tomoyuki, et al.
Publicado: (1988)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Treatment patterns and survival in metastatic castration‐sensitive prostate cancer in the US Veterans Health Administration
por: Freedland, Stephen J., et al.
Publicado: (2021)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
por: Pandit-Taskar, Neeta, et al.
Publicado: (2015)

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
por: Timmermand, Oskar Vilhelmsson, et al.
Publicado: (2014)

The Effects of Castration and Stilboestrol on Prostatic Tumours in Mice
por: Horning, E. S.
Publicado: (1949)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pdkqf080e96m3s6d6rgnqgiivi